Clinical Trials · NCT00426153

Octreotide in Severe Polycystic Liver Disease

CompletedPhase 2/Phase 3Octreotide (Approved)
Phase
Phase 2/Phase 3
Recruitment status
Completed
Sponsor
Mayo Clinic
Enrollment
42
Start date
Jan 2007
Locations
1 site, United States
Primary endpoint
Percent Change in Liver Volume
View Octreotide compound reference